Review of strategy through latest addition to the collection of diseases

Nordestgaard was the lead author of the 2013 EAS report. He is also an author on both the 1st and 2nd Danish reports. Nordestgaard put together a series of slides for the FH Foundation’s 2015 gathering. Some of the same slides are available in PDF form on the internet. The FH Foundation was and still is heavily funded by the pharmaceutical industry — Aegerion (in the past), Amgen, and Regeneron, for example. In Nordestgaard’s earlier work, the APOB and PCSK9 mutations were blended in with the LDL-Receptor mutations, and all three were called “FH” – ostensibly because, although the other two are not receptors, per se, they are associated with the receptor pathway.”  But now three of the four authors from the Danish reports – Nordestgaard, Benn, and Tybjaerg-Hansen – co-author a new report that includes another disease as FH which is not even associated with the receptor pathway: Lp(a).

Review of strategy through latest addition to the collection of diseases